Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone in diabetic kidney disease
NL-OMON47518Phase 3Active, not recruiting
- Sponsor
- Bayer
- Start
- Nov 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Kidney disease progression composite. Started Nov 2015; status: active, not recruiting.
02
Drugs
finerenone
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON47518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47518.